Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267553 | 0.96 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL26999198 | 0.96 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL2691313 | 0.96 | CHRM2 (0.46) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL15384702 | 0.85 | SLC6A2 (0.41) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL13595131 | 0.84 | CHRM2 (0.48) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL11514730 | 0.84 | CHRM2 (0.48) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL8058857 | 0.84 | CHRM2 (0.48) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL272354 | 0.84 | CHRM2 (0.48) | CHRM2CHRM4CHRM3SLC6A2SLC6A4 | |
| SCHEMBL28008749 | 0.82 | EPHX1 (0.37) | SLC6A2SLC6A4KDM4EALDH1A1MAPT | |
| SCHEMBL28008748 | 0.82 | EPHX1 (0.37) | SLC6A2SLC6A4KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| EP-1675864-B1 | PLATINUM COMPLEXES FOR THE TREATMENT OF TUMORS | UNIV SOUTH FLORIDA (US) | 2009-12-30 | — | — | EP | disclosed |
| CN-1882880-A | Aqueous resist composition | SHOWA DENKO KK (JP) | 2006-12-20 | — | — | CN | disclosed |
| CN-1813221-A | Resist composition | SHOWA DENKO KK (JP) | 2006-08-02 | — | — | CN | disclosed |
| US-20060154173-A1 | Resist composition | SHOWA DENKO K.K. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1644777-A2 | RESIST COMPOSITION | Showa Denko K.K. (JP) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005047978-A1 | AQUEOUS RESIST COMPOSITION | SHOWA DENKO K.K. (JP) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005003859-A2 | RESIST COMPOSITION | SHOWA DENKO K.K. (JP) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718602-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | CHRM2 4881/4885CHRM4 4880/4885CHRM3 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.